Intelligent Bio Solutions Reports Revenue Decline but Sees Improved Gross Profit in Q1 2025

Intelligent Bio Solutions Inc. (NASDAQ: GBS)

Company Overview:
Intelligent Bio Solutions Inc. (INBS) is focused on developing rapid, non-invasive medical testing technologies. They operate mainly through their products such as the Intelligent Fingerprinting Drug Screening System.

Income Statement Highlights (for the quarter ended March 31, 2025):
- Revenue: $728,867 (down from $823,800 in Q3 2024)
- Gross Profit: $341,368 (up from $178,489 in Q3 2024)
- Operating Expenses: $3,067,887 (down from $3,216,066 in Q3 2024)
- Net Loss: $(2,550,674) (down from $(2,986,765) in Q3 2024)
- Loss per share: $(0.44) (down from $(1.43) in Q3 2024)

Key Points:

• Revenue decline attributed to instability in the construction sector impacting reader sales.
• Gross profit margin improved to 46.84% from 21.67%, largely due to a shift towards higher margin cartridge products.
• Operating expenses decreased, primarily due to reduced legal and overhead costs.
• Government support income increased significantly, helping to offset losses.
• Net loss reduced due to increased gross profit and government subsidies, though total losses for the year are still substantial.

Financial Position:
- Cash and Cash Equivalents: $2,807,112 (down from $6,304,098 as of June 30, 2024)
- Current Assets: $5,107,331 (down from $8,534,243)
- Total Assets: $9,584,527 (down from $13,778,863)
- Total Liabilities: $4,640,761 (down from $5,595,672)
- Shareholders’ Equity: $4,943,766 (down from $8,183,191)

Positive Aspects:

• Improved gross profit reflects better cost management and a strategic shift towards higher-margin products.
• Government support income has risen, indicating funding availability for R&D initiatives.

Negative Aspects:

• Overall revenue decreased, primarily affected by sector-specific challenges.
• Continued net losses raise concerns about sustainability and the need for additional funding.
• Increased operational expenses in R&D may continue to pressure profits.

Conclusion:
Intelligent Bio Solutions Inc. shows progress in managing costs and increasing profitability in terms of gross margins. However, significant challenges remain, particularly regarding revenue generation and sustainable operational funding. The company must successfully navigate these hurdles while capitalizing on their government grants and innovative product offerings to solidify their market position.